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Dendritic cells are thought to regulate tolerance induction vs immunization by transferring Ags and peripheral signals to draining
lymph nodes (LN). However, whether myelin Ag transfer and presentation in LN occurs during demyelinating brain disease is
unknown. In this study, we demonstrate redistribution of autoantigens from brain lesions to cervical LN in monkey experimental
autoimmune encephalomyelitis (EAE) and in multiple sclerosis (MS). Immunohistochemical analysis revealed significantly more
cells containing myelin Ags in cervical LN of monkeys with EAE compared with those of healthy control monkeys. Myelin Ags
were observed in cells expressing dendritic cell/macrophage-specific markers, MHC class II, and costimulatory molecules. More-
over, these cells were directly juxtaposed to T cells, suggesting that cognate interactions between myelin-containing APC and T
cells are taking place in brain-draining LN. Indeed, myelin Ag-reactive T cells were observed in cervical LN from marmosets and
rhesus monkeys. Importantly, these findings were paralleled by our findings in human tissue. We observed significantly more
myelin Ag-containing cells in LN of individuals with MS compared with those of control individuals. These cells expressed APC
markers, as observed in marmosets and rhesus monkeys. These findings suggest that during MS and EAE, modulation of T cell
reactivity against brain-derived Ags also takes place in cervical LN and not necessarily inside the brain. A major implication is
that novel therapeutic strategies may be targeted to peripheral events, thereby circumventing the blood-brain barrier. The
Journal of Immunology, 2002, 169: 5415–5423.
C urrent views on the initiation of primary immune re-sponses hold that dendritic cells (DC)3 transfer Ags fromperipheral tissues into secondary lymphoid organs, where
they activate or make tolerant naive lymphocytes, depending on
the nature of the Ag and peripheral stimuli (1–7). Although this
concept is now fairly well established for model immunogens, mi-
crobial Ags, and apoptotic cell material, far less is known about
transfer and presentation of autoantigens in vivo during chronic
inflammatory disease. Autoimmune responses directed against my-
elin components are considered to be pivotal in the development
and perpetuation of multiple sclerosis (MS), but the nature of the
events leading to the activation of autoreactive lymphocytes is
largely unclear. This concerns both the anatomical site of Ag pre-
sentation and the features of APC involved. These issues are par-
ticularly relevant in relation to the continuous broadening of the
autoimmune response during chronic MS (8, 9), a phenomenon
known as epitope spreading. T cell reactivity is directed initially
toward a narrow set of myelin epitopes, but spreads to other
epitopes on the same Ag (intramolecular spreading) or to other
myelin Ags (intermolecular spreading). The pathogenic signifi-
cance of this process has been demonstrated in relapsing experi-
mental autoimmune encephalomyelitis (EAE) in mice (10–13).
The mechanism underlying epitope spreading is thought to involve
APC that present degraded myelin derived from the inflammatory
process in the CNS, but it is unknown where this presentation
occurs.
The CNS has long been regarded as an immune-privileged site
sequestered from the immune system by the blood-brain barrier
and the lack of lymphatic vessels, but it is now clear that Ags and
cells injected into the brain drain to secondary lymphoid organs
(14–16). Outflow of Ags from the brain occurs by interstitial fluid
and cerebrospinal fluid drainage to lymphoid organs via various
pathways. Ags in these fluids can drain via the blood to the spleen,
can escape along cranial nerves into the nasal lymphatics and drain
to the cervical lymph nodes (LN), and can escape along spinal
nerves to other LN.
The objective of this study was to determine whether myelin
Ag-containing APC are present in the cervical LN of monkeys
with EAE or individuals with MS and whether they might be in-
volved in modulation of T cell reactivity. Improved insight into
these mechanisms will elucidate tolerance induction vs autoimmu-
nity and facilitate the rational development of immunotherapy of
demyelinating disease.
We investigated the possible transfer and presentation of myelin
Ags in lymphoid organs during a demyelinating inflammatory pro-
cess in the CNS in nonhuman primates and in MS. The EAE model
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in common marmoset monkeys (Callithrix jacchus jacchus) mim-
ics human MS in its clinical presentation and in the radiological,
neuropathological, and immunological aspects of its brain white
matter lesions (17–20). The close phylogenetic relationship of
marmosets and humans makes EAE in this species a unique ex-
perimental system for detailed analysis of MS immunopathogen-
esis. Moreover, this outbred model has several useful features,
including 1) a 100% incidence of disease, which results from pre-
sentation of an encephalitogenic peptide by a monomorphic MHC
class II molecule (21), 2) primary demyelination occurring after
immunization with whole human myelin or with recombinant hu-
man myelin oligodendrocyte glycoprotein (rhMOG), 3) intramo-
lecular and intermolecular epitope spreading of the cellular and
humoral immune response (21, 22), and 4) the complete disease
spectrum being based on the intricate interplay between APC, T
cells, macrophages, and plasma cells (19, 23). In parallel to lym-
phoid organs of marmosets, we investigated cervical LN of rhesus
monkeys (Macaca mulatta) with acute EAE induced by myelin
oligodendrocyte glycoprotein (MOG) immunization (24) and cer-
vical LN from MS and control patients.
Materials and Methods
EAE tissues
Lymphoid organs and brain were isolated from common marmosets, rhesus
monkeys (M. mulatta), and cynomolgus monkeys (Macaca fascicularis)
raised at the Biomedical Primate Research Center (Rijswijk, The Nether-
lands), the German Primate Center (Go¨ttingen, Germany), and Inveresk
(Tranent, U.K.), as described previously (21, 24), under conditions ap-
proved by the Dutch, German, and British law, respectively, on animal
experimentation. All experimental procedures were approved by local In-
stitutional Animal Care and Use Committees. Tissues were obtained from
animals that were used for studies designed for other purposes, thus avoid-
ing sacrifice of animals for the purpose of the present study only. EAE was
induced in marmoset monkeys by immunization with 20 mg human whole
myelin or 0.1 mg rhMOG emulsified in CFA as described (17, 21). Adju-
vant control marmosets were immunized with 1 mg OVA (Sigma-Aldrich,
St. Louis, MO) in CFA. Emulsions were injected into the dorsal skin at four
different sites; two injections were given in both the inguinal and axillary
LN regions. EAE was induced in rhesus monkeys by immunization with
0.32 mg rhMOG or 0.1 mg MOG34–56 (human MOG peptide (phMOG)) in
CFA as described (24). The MOG/CFA emulsion was injected into the
dorsal skin at 10 different spots on the back. Adjuvant control rhesus mon-
keys were immunized with 3–5 mg bovine type II collagen in CFA as
described (25). All myelin Ag-immunized animals were examined daily for
clinical symptoms of EAE by a trained observer. Brain inflammation was
visualized by magnetic resonance imaging and/or (immuno-)histochemis-
try as described previously (17, 26). According to these examinations, all
animals immunized with myelin Ags had clinically active EAE and in-
flammatory foci in their brain at the time of necropsy. Deep cervical LN
and spleens were isolated from animals sacrificed by an i.v. injection of
pentobarbital during deep ketamine sedation. In addition, axillary and in-
guinal LN, draining the immunization sites, were isolated for comparison.
All lymphoid tissues were immediately frozen in liquid nitrogen and stored
at 80°C until use.
Human tissues
Human cervical LN (one to five per patient) were taken from two patients
with chronic MS and two control patients at autopsy, and were provided by
the Netherlands Brain Bank. Control patient S01/216 died of cancer of the
urinary tract, whereas control patients S01/228 was diagnosed with hered-
itary motor and sensory neuropathy type 1. After removal, LN were snap
frozen in liquid nitrogen and stored at 80°C until use. From each patient,
at least five sections were stained for each marker for quantification.
Histochemistry
Myelin degradation products were detected with oil-red O (ORO), which
stains neutral lipids, as previously described (27). Neutral lipids as visu-
alized by ORO are not just a marker for degraded myelin, but are relevant
to pathogenesis, because self glycolipids are T cell autoantigens in MS
(28). Briefly, cryosections (6 m) were stained with 0.3% (w/v) ORO
(Gurr, London, U.K.) in 60% 2-propanol and counterstained with hema-
toxylin. Acid phosphatase, a marker of macrophages, was detected in ac-
etone-fixed sections, as previously described (29), using naphtol-AS-BI-
phosphate (Sigma-Aldrich) as substrate.
Immunohistochemistry
Immunohistochemistry was performed as described previously (26, 30)
with slight modifications. Sections were fixed in 4% paraformaldehyde in
PBS (pH 7.4) and treated with 0.02% (v/v) H2O2 in PBS to eliminate
endogenous peroxidase activity. Any remaining endogenous peroxidase
activity was demonstrated with 4-chloro-1-naphthol (dark blue reaction
product; Sigma-Aldrich). Sections were incubated with primary Abs over-
night in humidified atmosphere, followed by biotinylated-secondary Abs
for half an hour and HRP-conjugated avidin-biotin complex (ABC-HRP;
DAKO, Glostrup, Denmark) for 1 h. Labeled cells were stained with either
3-amino-9-ethylcarbazole (red reaction product; Sigma-Aldrich) or diami-
nobenzidine (brown reaction product; Sigma-Aldrich). Finally, sections
were counterstained with hematoxylin and embedded in glycerol-gelatin.
Double-labeling of cells was performed, as described previously (30), with
alkaline phosphatase-conjugated secondary Abs and a substrate solution
containing Fast Blue BB Base (blue reaction product; Sigma-Aldrich).
The primary Abs used for immunohistochemistry were polyclonal rab-
bit anti-bovine myelin basic protein (MBP; kindly provided by Dr. J.
Bajramovic¸, Netherlands Organization for Applied Scientific Research
(TNO), Prevention and Health, Leiden, The Netherlands), rabbit anti-CD3
(DAKO) and mAbs directed against the encephalitogenic epitope of pro-
teolipid protein (PLP) in SJL/J mice, i.e., PLP139–151 (J1/03; Ref. 31),
MHC class II (L243; BD Biosciences, San Diego, CA), and the APC mark-
ers CD40 (5D12; Tanox Pharma, Amsterdam, The Netherlands), CD68
(KP-1; DAKO), CD83 (HB15A; Immunotech, Westbrook, ME), CD86
(1G10; kindly provided by Innogenetics, Gent, Belgium), DC-SIGN
(AZN-D1; kindly provided by Dr. Y. van Kooyk, University Medical Cen-
ter St. Radboud, Nijmegen, The Netherlands), and CCR7 (2H4; BD
PharMingen, San Diego, CA). Secondary biotinylated Abs were rabbit-
anti-mouse Ig (DAKO), donkey-anti-rabbit Ig (Amersham, Buckingham-
shire, U.K.), horse-anti-mouse Ig (Vector Laboratories, Burlingame, CA),
alkaline-phosphatase conjugated rabbit-anti-mouse Ig, goat-anti-rabbit Ig
(both from DAKO), and rabbit-anti-goat Ig (Southern Biotechnology As-
sociates, Birmingham, AL).
Quantitation of stained cells
To calculate the number of ORO-, anti-MBP-, or anti-PLP-stained cells per
square millimeter in cervical LN sections, the cells were counted and the
area of the sections was determined using a VIDAS-RT image analysis
system (Kontron Elektronik/Carl Zeiss, Weesp, The Netherlands). Area
measurements were performed using a 2.5-fold magnification objective.
T cell proliferation assays
Proliferation assays with cervical LN cells were performed essentially as
previously described (21, 32). Briefly, LN cell suspensions were prepared
from aseptically removed cervical LN from sacrificed marmoset and rhesus
monkeys with EAE. LN cells were cultured with 10 g/ml rhMOG or
phMOG in HEPES-buffered RPMI 1640 (Life Technologies, Glasgow,
U.K.) supplemented with 10% FCS (Flow Laboratories, McLean, VA), 10
mM MEM with nonessential amino acids, 2 mM L-glutamine, 100 U/ml
penicillin G, 100 g/ml streptomycin, and 2  104 M 2-ME (all from
Life Technologies). Marmoset cervical LN cells were restimulated with
EBV-transformed autologous B cells and 10 g/ml rhMOG. Proliferation
of marmoset cervical LN cells was tested after one or two rounds of re-
stimulation, whereas proliferation of rhesus cervical LN cells was tested
directly after the first round of stimulation. Marmoset and rhesus LN cells
(2  104 cells/well) were seeded with or without relevant Ag in the pres-
ence of EBV-transformed autologous B cells (2  104 cells/well) or irra-
diated spleen cells (2  105cells/well), respectively, in 96-well flat-bottom
plates (Greiner, Solingen, Germany) for 48 h and subsequently pulsed with
0.5 Ci [3H]thymidine for 18 h. [3H]thymidine incorporation was mea-
sured in a matrix 9600 beta-counter (Packard, Meriden, CT).
Statistics
Differences in the number of myelin Ag-containing cells in cervical LN
between treatment groups were determined by a two-tailed Mann-Whitney
test. The number of stained cells in the axillary and inguinal LN and spleen
per visual field was scored using a 10-fold objective in a semiquantitative
manner as: , no positive cells; /, 1–5 positive cells; , 6–20 positive
cells; , 21–50 positive cells; or , 50 positive cells.
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Results
EAE and CNS pathology in common marmosets
To investigate the drainage of myelin degradation products to sec-
ondary lymphoid organs during active inflammation of the CNS, as
well as under normal physiological conditions, brain tissue, dif-
ferent LN, and spleens were isolated from nonimmunized marmo-
set and cynomolgus monkeys, from marmoset and rhesus monkeys
immunized to develop EAE, and from adjuvant control marmoset
and rhesus monkeys. According to clinical, radiological, and (im-
muno-)histochemical examination, all myelin Ag-immunized
monkeys possessed cellular infiltrates in the CNS at the time of
sacrifice (data not shown). (Immuno-)histochemical analysis of in-
flammatory foci in EAE brains showed the presence of ORO-pos-
itive cells (Fig. 1A), i.e., cells containing neutral lipids as a result
of myelin degradation, and PLP-containing cells (Fig. 1B), similar
to previous findings in marmoset EAE (17). In this respect, the
neuropathology of marmoset EAE closely mimics the situation in
MS, where abundant ORO-positive cells are also found in active
brain lesions (33, 34). In the EAE lesions, both ORO and PLP
staining were found mainly in the cytoplasm of large cells with a
morphology closely resembling macrophages. Furthermore, EAE
lesions contained numerous cells expressing MHC class II, acid
phosphatase, CD40 (26), and CD83 (data not shown), indicative of
the presence of APC.
To determine whether myelin Ags gain access to brain-draining
lymphoid organs during demyelinating EAE, sections of cervical
LN and spleen were stained with ORO to detect degraded myelin
lipids, with a polyclonal antiserum against MBP, or with a mAb
against PLP139–151, a classical encephalitogenic epitope in SJL/J
mice. In the cervical LN of both myelin- and MOG-immunized
marmosets, a large number of ORO- and PLP-positive cells were
detected (Fig. 1, C and D, respectively).
Thus, in marmosets with EAE, myelin Ags are observed not
only in the brain, as expected, but also in brain-draining
cervical LN.
Myelin Ag load in cervical LN of marmosets and rhesus
monkeys
To investigate whether the presence of myelin APC correlates with
the presence of demyelinating CNS disease, the number of ORO-
positive cells in cervical LN of marmosets with EAE induced by
human whole myelin or rhMOG immunization was compared with
those found in healthy control monkeys. A striking difference was
found in the number of ORO-positive cells, which were detected in
nine of 10 marmosets with EAE, but in none of the untreated
marmosets ( p  0.05) (Fig. 2A). Moreover, a significantly higher
number of MBP- and PLP-containing cells was observed in the
cervical LN of marmosets with EAE as compared with those of the
control group ( p  0.05) (Fig. 2, B and C).
Next, we compared the presence of myelin Ags in cervical LN
of rhesus monkeys with EAE or collagen-induced arthritis, to ex-
clude the possibility that myelin Ags were present in these LN as
a result of the administration of adjuvant. We chose to examine the
LN of rhesus monkeys, because we were unable to retrieve them
from marmoset monkeys immunized with OVA in adjuvant. Strik-
ingly, the number of MBP- and PLP-containing cells was mark-
edly higher ( p  0.05) in the LN of rhesus monkeys with EAE
induced by rhMOG or phMOG immunization as compared with
those of the adjuvant control animals (Fig. 3, A and B). However,
ORO-positive cells were not detected in cervical LN of rhesus
EAE and control monkeys. Furthermore, a paucity of myelin Ag-
containing cells was found in cervical LN (n  10) of normal
cynomolgus monkeys, a species related to rhesus monkeys (data
not shown).
Together, these results demonstrate that myelin Ags in the cer-
vical LN result from the demyelination of the CNS and not from
the immunization itself, nor from normal myelin turn-over or local
neurons innervating the LN. The finding that MBP and PLP are
present in the cervical LN of marmoset and rhesus monkeys im-
munized with MOG only, shows that myelin Ags in this lymphoid
organ are derived from the inflamed CNS rather than from the
injected emulsion.
Myelin-containing cells in cervical LN express APC markers
and colocalize with T cells
Most myelin Ag-containing cells in the cervical LN of marmoset
and rhesus monkeys with EAE were detected in the medulla. How-
ever, some myelin Ag-containing cells were found in the subcap-
sular sinus, the site where leukocytes enter the LN with the afferent
lymph, and in extrafollicular areas of the cortex, the site where
interaction of APC with T cells occurs (data not shown). Myelin
Ags were found mostly in the cytoplasm of large cells with a
FIGURE 1. Myelin Ag-containing cells in
brain and brain draining LN. In situ analysis of
myelin Ag-containing cells in brain (A and B)
and cervical LN (C and D) from marmosets with
MOG-induced EAE. A, Cells containing neutral
lipids, stained red by ORO, were found in the
brain parenchyma marmosets with EAE. B,
Cells containing the myelin protein PLP were
observed in brain parenchyma. C, ORO-positive
cells were found in cervical LN of marmosets
with EAE. D, Macrophage-like cells containing
myelin proteins were also present in the cervical
LN as demonstrated by PLP staining. Magnifi-
cation: A, 315; B–D, 500.
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morphology resembling macrophages, similar to the findings in the
brain. Indeed, most MBP- and PLP-positive cells expressed mac-
rophage markers, including the lysosomal enzyme acid phospha-
tase (AP, Fig. 4A) and CD68 (Fig. 4B). To determine whether
myelin Ag-containing cells in the cervical LN of monkeys with
EAE represented cells with the potential to present Ags to CD4
T cells, double-labeling studies were performed with Abs cross-
reactive with marmoset (MHC class II, CD40, CD83) and rhesus
(CD40, CD86, DC-SIGN, CCR7) surface molecules. Myelin-con-
taining cells displayed features of professional APC, including ex-
pression of the DC markers CD83 (Fig. 4C) and DC-SIGN (Fig.
4D), that are essential in DC-induced T cell proliferation (35, 36).
Staining for both acid phosphatase activity and CD83 revealed
many double-positive cells in the cervical LN (data not shown),
indicating that macrophage and DC markers are coexpressed by
cells loaded with myelin Ags. The majority of MBP- and PLP-
containing cells in the cervical LN also showed cell surface ex-
pression of MHC class II (Fig. 4E) and of the costimulatory mol-
ecules CD40 (Fig. 4F) and CD86 (not shown). In addition, myelin
Ag-containing cells expressed the chemokine receptor CCR7 (Fig.
4G) and the receptor for the LN-derived chemokines CCL19
(MIP-3 or ELC) and CCL21 (6-C-kine or SLC) driving DC mi-
gration (37).
To assess whether myelin Ag-containing APC colocalized with
T cells, indicative of cognate interaction, double-labeling for PLP
and CD3 was performed on cervical LN of monkeys with EAE. In
the medulla, numerous PLP-positive cells were found in juxtapo-
sition with T cells (Fig. 4H). PLP-containing cells were also found
in the subcapsular sinus at the border of the T cell area and occa-
sionally within the T cell areas of the cervical LN. These results
demonstrate that myelin Ags are present in the cervical LN in cells
that have the characteristics of mature professional APC and that
are in direct contact with T cells.
Myelin-specific T cells in cervical LN of marmosets and rhesus
monkeys with EAE
To determine whether cervical LN contain myelin-specific T cells
besides myelin Ag-containing APC, cervical LN cells of marmoset
and rhesus monkeys with EAE were tested for MOG-specific pro-
liferative responses. Because primary cervical LN cells showed
low proliferative responses as expected, proliferation was deter-
mined after a primary stimulation or after one or two rounds of
restimulation. Positive responses (stimulation index 2) were
found with cervical LN cells from three of four marmosets and all
rhesus monkeys (Fig. 5), indicating that myelin-specific T cells are
present in these brain-draining LN.
Myelin Ags in spleen, axillary, and inguinal LN
In addition to the cervical LN, the spleen and the axillary and
inguinal LN of marmoset monkeys were analyzed for the presence
of myelin components to determine whether myelin Ags gain ac-
cess to other secondary lymphoid organs (Table I). ORO-positive
cells were detected in none of the spleens of myelin- or rhMOG-
immunized marmosets, nor in those of OVA-immunized marmo-
sets or untreated monkeys. However, a significant number of PLP-
containing cells and a few MBP-containing cells were detected in
FIGURE 2. Myelin Ag load in marmoset cervical LN. The density of
cells containing neutral lipids stained by ORO (A), MBP (B), and PLP (C)
in cervical LN of marmosets with EAE, immunized with either human
whole myelin (E) or rhMOG (‚), was compared with that of healthy mar-
moset monkeys. Significantly more ORO-, MBP-, and PLP-containing
cells were observed in cervical LN of marmosets with EAE as compared
with those of control marmosets (p  0.05). The number of cells per
surface area was determined by counting stained cells and measuring the
area of the sections at 2.5-fold magnification using the VIDAS-RT image
analysis system.
FIGURE 3. MBP- and PLP-containing cells in rhesus cervical LN. Cer-
vical LN of rhesus monkeys with EAE, immunized with rhMOG (‚) or
phMOG (Œ), were compared with those of adjuvant controls with collagen-
induced arthritis (CIA). Significantly more MBP- and PLP-positive cells
were observed in cervical LN of rhesus monkeys with EAE as compared
with those of OVA-immunized control monkeys. The number of MBP-
containing cells (A) and PLP-containing cells (B) per surface area was
determined as described in the legend for Fig. 2.
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the red pulp and around vessels within the spleens of marmosets
with EAE. In contrast, the spleens of adjuvant controls and un-
treated monkeys were almost completely devoid of cells contain-
ing MBP and PLP. These results provide further evidence that
myelin Ags gain access to brain-draining lymphoid organs as a
direct result of CNS inflammation.
Analysis of axillary and inguinal LN from myelin Ag-immu-
nized and OVA-immunized marmosets revealed a complete ab-
sence of ORO-positive cells (Table I), similar to the findings in the
spleen. Comparable small-to-moderate numbers of cells containing
MBP and PLP were detected in the LN of marmosets with EAE as
well as adjuvant control marmosets. These results indicate that
myelin Ags in these LN, which drain the immunization sites, may
result from a response to the adjuvant administration rather than
from the inflammatory process in the CNS.
Myelin-containing cells in cervical LN of MS patients
To determine whether the findings in two nonhuman primate EAE
models appropriately reflect events in MS, we examined cervical
LN of two MS patients with active disease and those of two control
patients for the presence of myelin Ags. Cervical LN from both
MS patients contained cells loaded with MBP and PLP (Fig. 6, A
and B, respectively). As in rhesus EAE, ORO staining revealed a
paucity of cells containing neutral lipids from degraded myelin.
Myelin Ag-containing cells expressed APC markers such as CD40
and acid phosphatase (Fig. 6, C and D, respectively). Importantly,
significantly more PLP-containing cells were observed in the cer-
vical LN of both MS patients compared with those of both control
patients (Table II) ( p 0.005). The same pattern was observed for
MBP. However, although more MBP-containing cells were ob-
served in MS patients, this was not significantly more than control
patient S01/216. Interestingly, control patient S01/218, who suf-
fered from peripheral neuropathy, did have significantly fewer
MBP-containing cells compared with both MS patients ( p 
0.05). These results imply that, during MS, the presence of intra-
cellular myelin Ags in APC is not restricted to the brain but is also
found in APC in cervical LN, similar to what was observed with
marmoset and rhesus EAE.
Discussion
Autoimmunity toward myelin and other CNS components is con-
sidered to play a pivotal role in the development and perpetuation
of MS, but the anatomical site of Ag presentation and the type of
APC involved in the activation of autoreactive lymphocytes is still
largely unclear. In this study, we explored the redistribution of
FIGURE 4. Myelin Ags are present in immu-
nocompetent APC in cervical LN. Myelin Ag-
containing cells in cervical LN of marmosets with
EAE (A, C, E, F, and H) or rhesus monkeys with
EAE (B, D, and G) were characterized by (im-
muno-)histochemical procedures. APC markers
were stained in combination with staining for
MBP or PLP (no counterstaining). A, Most PLP-
containing cells (blue) also express the macro-
phage marker acid phosphatase (red, arrows). B,
In the rhesus cervical LN, many PLP-containing
cells (blue) expressed the macrophage marker
CD68 (red). Double-labeled cells are indicated
with arrows, a single CD68 cell is indicated with
an arrowhead. C, Double-labeled cells for MBP
(blue) and CD83 (red) are frequently found (ar-
rows) but single-stained cells are also observed
(CD83, arrowhead). D, Besides CD83 expression,
the majority of PLP-containing cells (blue) also
express DC-SIGN (red); double-positive cells are
stained purple. E, Cell surface expression of MHC
class II (stained blue) was found throughout the
LN and a subset of class II-positive cells contain
myelin Ags (PLP, red). Double-labeled cells are
indicated with arrows, and single-stained cells
(MHC II) with arrowheads. F, Expression of
CD40 (red) and CD86 (not shown) was found on
most myelin Ag-containing cells (MBP stained
blue) Double-labeled cells are indicated with ar-
rows, single-stained cells (CD40) with arrow-
heads. G, Example of CCR7 expression (red) on a
PLP-containing cells (blue). H, Myelin-contain-
ing cells (PLP stained red) were found in direct
contact with CD3 T cells (blue). Magnification:
A–H, 500.
5419The Journal of Immunology
myelin components during demyelinating EAE in nonhuman pri-
mates and MS, and characterized the cells loaded with myelin Ags
in the draining LN. Using demyelinating EAE models, we dem-
onstrated that 1) myelin Ags (neutral lipids, MBP, and PLP) are
present in brain-draining lymphoid organs as a result of a demy-
elinating process in the CNS, 2) myelin Ag-containing cells dis-
play characteristics of professional APC, 3) myelin Ag-containing
cells are in direct contact with T cells, and 4) myelin Ag-reactive
T cells are present at this site. These results indicate that myelin
Ags do not remain sequestered behind the blood-brain barrier dur-
ing EAE but are transferred to sites that are optimally equipped for
priming of myelin-specific T and B cells. Moreover, these data
strongly suggest that cognate interactions between these myelin-
containing APC and T cells take place in brain-draining lymphoid
organs such as the cervical LN. Subsequently, reactivation of my-
elin-specific Ag-experienced T cells occurs locally in the CNS by
virtue of resident APC-presenting myelin proteins (38, 39). Im-
portantly, we also observe significantly more myelin Ag-contain-
ing cells in cervical LN of patients with MS compared with those
of control patients, suggesting a similar role of cervical LN in the
regulation of T cell responses. However, in this study, only a lim-
ited number of human cervical LN were available for analysis and
more tissues should be assessed in the future.
Recently, we have provided evidence that MOG-induced EAE
in marmosets is associated with intramolecular epitope spreading
of the T cell response (21). MOG-induced EAE is initiated by the
presentation of an encephalitogenic peptide of the extracellular
domain of MOG (MOG14–36) in the context of a monomorphic
Mhc-DR molecule, Caja-DRB*W1201 (21). This disease-initiat-
ing step is followed by spreading to other MOG epitopes. The
present finding that cervical LN of MOG-immunized marmoset
and rhesus monkeys contain cells loaded with MBP and PLP
strongly suggests that the priming of lymphocytes specific for (in-
tramolecular and intermolecular) spreading epitopes takes place in
this brain-draining LN. The observed difference in myelin content
of cells in the cervical LN of marmoset vs rhesus monkeys may be
related to the different pathogenesis of EAE in these species; al-
though the exact mechanisms underlying myelin breakdown in
rhesus and marmoset EAE are unknown, rhesus EAE is charac-
terized by acute inflammatory necrosis of the white matter with
profound influx of granulocytes, rather than chronic demyelination
(40). Local release of granulocyte enzymes and reactive oxygen
species may affect myelin degradation. Alternatively, the differen-
tial persistence of myelin lipids within cells may result from spe-
cies differences in the intracellular degradation process.
Active demyelinating lesions in both MS patients and marmo-
sets with EAE are characterized by activated macrophages loaded
with neutral lipids from degraded myelin, MBP, and PLP (17, 33,
34, 41), of which the eventual fate is unclear. Furthermore, MBP
levels in CSF are elevated during relapsing-remitting MS (42).
Studies tracing the outflow pathways of the brain in healthy ani-
mals revealed that both injected cells (macrophages and lympho-
cytes) and injected proteins and other substances drain preferen-
tially to the cervical LN (14, 15, 43, 44). These findings imply that
the myelin Ags found in the cervical LN within cells with DC- and
macrophage-like characteristics (Figs. 1 and 4) have been ingested in
the LN or have been transported from the brain to the LN by phago-
cytic cells, such as brain “resident” microglia, perivascular cells, DC
from the meninges or choroid plexus (16, 38), or brain-infiltrated
Table I. Myelin Ag-containing cells are present in other LN and spleena
Species Immunogen Myelin Component Spleen Axillary LN Inguinal LN
Marmoset Myelin Neutral lipids – – –
MBP /–  
PLP139–151   
Marmoset MOG Neutral lipids – – –
MBP /–  
PLP139–151   
Marmoset OVA Neutral lipids – – –
MBP – /– 
PLP139–151   
Marmoset None Neutral lipids – ND ND
MBP – ND ND
PLP139–151 – ND ND
Cynomolgus None Neutral lipids – – –
MBP – /– /–
PLP139–151 – /– /–
a Sections of secondary lymphoid organs were scored for the presence of myelin Ag-containing cells (– to ; ND, Not
determined; see Materials and Methods). The analysis included groups of five marmosets immunised with whole myelin, six
marmosets immunised with rhMOG, two marmosets immunized with OVA, one untreated marmoset, and five untreated cyno-
molgus monkeys.
FIGURE 5. Myelin Ag-specific T cells in cervical LN of monkeys with
EAE. MOG-specific responses of cervical LN T cells of six individual
marmoset and rhesus monkeys with EAE induced by immunization with
human whole myelin, rhMOG, or phMOG. Cervical LN cells were cultured
with 10 g/ml rhMOG or phMOG. Rhesus cervical LN cells were tested
after primary stimulation, whereas marmoset cervical LN cells were as-
sayed after one or two rounds of restimulation. The specific proliferative
responses are expressed as the stimulation index, defined as cpm in cultures
with 10 g/ml Ag divided by cpm without Ag. Dotted line indicates stim-
ulation index of two; stimulation indices of 2 were considered relevant.
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DC and macrophages. The latter notion is supported by studies on
inflammatory responses in the kidney (45) and peritoneal cavity
(46), which demonstrated that, during inflammatory conditions,
macrophages migrate from these sites to the draining LN. Inter-
estingly, Randolph et al. (4) showed, in an elegant in vivo study,
that phagocytes at inflammatory sites were not merely macro-
phages but a substantial number of these cells differentiated into
DC upon migration to the T cell area of the draining LN. This may
explain the mixed phenotype (CD83 and acid phosphatase-posi-
tive) of DC-macrophage-like cells containing myelin Ags in the
cervical LN observed in our study. The observation that myelin
Ag-containing cells express CCR7 suggests that these cells have
migrated to the LN in a regulated manner (47). Further studies are
required to determine the identity of the cells containing myelin
Ags in the cervical LN. In addition to transfer in phagocytotic
cells, myelin Ags in LN DC may also result from Ag transfer, i.e.,
uptake of Ags released by migratory cells, as shown in other sys-
tems (48, 49). Alternatively, myelin Ags may have drained to other
locations, including LN, and been carried subsequently to the cer-
vical LN. However, our data from spleens and other LN of mar-
moset monkeys (Table I) suggests that this would apply only for
myelin proteins. Although MBP and PLP can be transiently ex-
pressed in various types of leukocytes during immune-stimulatory
conditions (50–52), the additional presence of neutral lipids from
degraded myelin within APC in the cervical LN makes this an
unlikely explanation for our findings. The presence of myelin pro-
teins within cells in the inguinal, axillary, and cervical LN of
OVA- and collagen-immunized animals may result from normal
myelin turnover (53) or be explained by such de novo expression
of MBP and PLP in response to the injection of CFA, which exerts
strong effects on phagocytic cells (54). Collectively, the findings of
the present study imply that, during EAE in marmoset and rhesus
monkeys, phagocytic cells take up myelin in brain lesions, migrate
to the cervical LN and the spleen, and present myelin Ags at these
sites to T cells.
Ample evidence is now available that there is functional spe-
cialization of individual LN from distinct anatomical sites. The
cervical LN are instrumental in the induction of nasal tolerance
(55), i.e., removal of cervical LN abrogated tolerance induction,
which could be restored only by transplantation of cervical LN, but
not of other LN. Cervical LN also play an important role in the
induction of immune responses to brain-derived Ags (14, 56–58).
Interestingly, Ags injected into the CNS evoke a deviant systemic
immune response that is deficient in Ag-specific delayed-type hy-
persensitivity (59, 60). Recently, it was shown that this deviated
immune response could be transferred to naive animals by cervical
LN cells from donors that received an injection of Ag in the brain
8 days earlier (60). We hypothesize that, during EAE, inflamma-
tory signals from the CNS environment prevent the induction of a
deviant immune response (2, 3). The significance of cervical LN in
the development of EAE is demonstrated by the finding that com-
plete removal of the cervical LN markedly reduced the severity of
cryolesion-enhanced EAE in Lewis rats (61). Moreover, there are
indications that encephalitogenic T cells primed in the cervical LN
may preferentially target the brain (62). The results of our study
support the importance of the cervical LN in EAE in the modula-
tion of autoreactivity.
Strategies to treat MS with therapeutic Abs directed against co-
stimulatory molecules and cytokines are currently under develop-
ment (19, 63). To interfere with effector functions of T cells and
macrophages, it is generally assumed that such immunotherapeu-
tics should necessarily reach the lesions in the CNS by crossing the
blood-brain barrier. However, the results of the present study in-
dicate that the cervical LN, which may be accessible via nasal
drainage and the circulation, may also serve as a local target for
immunotherapy of demyelinating diseases. In this respect, it is
interesting that nasal application of low doses of cytokines such as
IL-10 ameliorated relapsing EAE in DA rats (64).
In conclusion, the findings of the present study imply that, dur-
ing MS and EAE in marmosets and rhesus monkeys, myelin Ags
FIGURE 6. Myelin Ag-containing cells are
present in cervical LN of MS patients. Cervical
LN of MS patient with active disease contain
numerous cells loaded with MBP (A) and PLP
(B). PLP-containing cells express APC makers
such as CD40 (C) and acid phosphatase (D).
Sections shown in A and B are counterstained
with hematoxylin. Magnification: A and B,
315; C and D, 500.
Table II. Quantification of myelin Ag-containing cells in cervical LN of
MS patients and control patients
Patient MS
PLP-Containing
Cells/mm2
MBP-Containing
Cells/mm2
S01/014 Yes 5.3 3.0 1.5  1.4
S01/214 Yes 4.4 1.4 2.0  1.2
S01/228 No 0.8 0.4 0.2  0.2
S01/216 No 1.8 1.3 0.8  0.4
At least five sections of one to five cervical LN per individual were scored for PLP
and MBP-positive cells.
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are transferred to the cervical LN. Subsequently, they can be pre-
sented to T cells by APC, resulting in modulation of T cell reac-
tivity and proliferation. Future studies are warranted to elucidate
the mechanisms involved. The monkey EAE models will be a
valuable tool to study these mechanisms of Ag transfer and the role
of cervical LN in the modulation of T cell responses during MS
and may lead to the development of novel therapeutic strategies.
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